Symptomatic Loiasis When Diethylcarbamazine (DEC) Has Not Achieved Cure
In patients with symptomatic loiasis and a microfilarial load below 8,000 microfilariae per mL of blood, diethylcarbamazine (DEC) is the established first-line treatment. When a full course of DEC does not deliver the expected cure, a defined second-line protocol applies.
Clinical Scenario
Symptomatic loiasis with a microfilarial load of fewer than 8,000 microfilariae per mL of blood. At this microfilarial burden, available data show that the risk of fatal encephalopathy associated with DEC treatment approaches zero.
Previous Treatment — Goals Not Met
First-line therapy with diethylcarbamazine (DEC) did not achieve cure — defined as resolution of symptoms, resolution of eosinophilia, and decreasing antifilarial antibody titers. This failure to reach the defined treatment goals is the trigger for escalation to the next treatment line.
Next-Step Treatment Approach
There is evidence supporting albendazole, given orally over a defined course, as an effective alternative for loiasis that is refractory to DEC. The treatment goal remains the same: cure, defined as resolution of symptoms, resolution of eosinophilia, and decreasing antifilarial antibody titers. The complete regimen — including dosing, frequency, and duration — is available in the full structured protocol.
References
- Symptomatic loiasis with MF/mL <8,000
- Available data demonstrate that the risk of fatal encephalopathy in patients treated with DEC with microfilarial loads <8,000 microfilariae per mL approaches zero.
- There is some evidence that albendazole given twice daily for 21 days may be an effective treatment for loiasis that is refractory to DEC treatment.
View source ↗